Introduction
Visit-to-visit low-density lipoprotein cholesterol (LDL-C) variability has recently sparked interest as a possible predictor of cardiovascular events. Recent analyses of large clinical trials and population cohorts have demonstrated that higher lipoprotein cholesterol variability is associated with death, myocardial infarction (MI), stroke, and cognitive dysfunction. [1] [2] [3] These findings appear to be independent of the treatment effect with 3-hydroxy-3-methylglutaryl coenzyme A (HMG Co-A) reductase inhibitors (statins), suggesting cholesterol variability as a possible marker of residual risk for adverse outcomes among high-risk patients. However, mechanisms linking LDL-C variability and increased cardiovascular risk remain unknown, and whether these findings can be extended to a broader lipoprotein profile has IVUS examination permits the examination of the effects of intraindividual lipid variability upon coronary atheroma progression. We tested the hypothesis that intra-individual lipoprotein variability [measured as LDL-C, non-high density lipoprotein cholesterol (non-HDL-C), high-density lipoprotein cholesterol (HDL-C), total cholesterol (TC) to HDL-C ratio or TC/HDL-C, and apolipoprotein B (ApoB)] associates with coronary atheroma progression-regression and clinical outcomes.
Methods

Study population
This analysis included all participants in nine clinical trials assessing the impact of medical therapies on serial changes in coronary atheroma burden using IVUS. 
Acquisition and analysis of serial intravascular ultrasonography images
The acquisition and serial analysis of IVUS images in each of these trials has been previously described in detail. Briefly, target vessels for imaging were selected if they contained no luminal stenosis of >50% angiographic severity within a segment of at least 30 mm length. Imaging was performed within the same coronary artery at baseline and at study completion, which ranged from 18 to 24 months. Imaging in all trials was screened by the Atherosclerosis Imaging Core Laboratory of the Cleveland Clinic Coordinating Center for Clinical Research (C5R). Patients meeting pre-specified requirements for image quality were eligible for randomization. An anatomically matched segment was defined at the two time points on the basis of proximal and distal side branches (fiduciary points). Cross-sectional images spaced precisely 1 mm part were selected for measurement. Leading edges of the lumen and external elastic membrane (EEM) were traced by manual planimetry. Plaque area was defined as the area occupied between these leading edges. The accuracy and reproducibility of this method have been reported previously. 14 The percent atheroma volume (PAV) was determined by calculating the proportion of the entire vessel wall occupied by atherosclerotic plaque, throughout the segment of interest as follows:
Statistical analysis
Continuous variables are reported as mean ± SD. Categorical variables are reported as frequency and percent. A paired t-test was used to test if the mean change in lipids from baseline was different from zero. While adjusting for trial and baseline PAV, a mixed model was used to test if the least-squares mean annualized change in PAV from baseline was different from zero. Multivariable mixed models were constructed in order to assess the association of lipid variability and average on-treatment lipid values with annualized change in PAV (DPAV). Separate models were run for lipid variability and average follow-up lipid values due to multicollinearity. In order to compare regression coefficients across models, continuous data were first standardized to have a mean of 0 and a SD of 1, and then the models were run on this standardized data. Variables adjusted for in each model included baseline lipid, baseline PAV, region, number of follow-up measure for each respective lipid (3 vs. 4), age, gender, body mass index (BMI), diabetes, concomitant statin use, and clinical trial. Beta coefficients with 95% confidence intervals (CI) are reported. Similarly, logistic regression models were constructed to assess the association of lipid variability and average on-treatment lipid values with any plaque progression. The same standardization and adjustments were made in these models as above. Odds ratio with 95% CI are reported.
The Kaplan-Meier (KM) curves illustrate the first incidence of major adverse cardiovascular event (MACE; defined as death, MI, stroke, urgent revascularization for acute coronary syndrome, and hospitalization for unstable angina) stratified by quartiles of the SD of each lipid. The data for the curves are censored at 24 months. The KM estimates of cumulative incidence of MACE are reported by quartile on each plot with log-rank tests performed to assess any difference in estimates among quartiles. Patients who received torcetrapib in ILLUSTRATE were excluded from the MACE sensitivity analysis due to torcetrapib's toxic effect. 15 All tests were two-tailed with a 0.05 significance level. Analyses were done using SAS version 9.4 (SAS Institute Inc., Cary, NC, USA). Table 1 describes baseline demographics, clinical characteristics, and medication use of the pooled study population (n = 4967). Mean age was 58 ± 9 years, 28% were women, 29% had diabetes mellitus, and the mean BMI was 30.8 ± 5.8 kg/m 2 . Notably, 74% received prior statin therapy, and concomitant (on-trial) rates of statins, aspirin, b-blockers, and angiotensin-converting enzyme inhibitor/angiotensin receptor blocker use were 96%, 94%, 76%, and 68%, respectively. Table 2 describes baseline and follow-up for lipid measurements and plaque volume. In the overall population, the achieved levels of LDL-C, non-HDL-C, HDL-C, TC-HDL-C, ApoB, and haemoglobin A1c were 83 ± 28 mg/dL, 111 ± 33 mg/dL, 48 ± 15 mg/dL, 3.6 ± 1.2, 80 ± 25, and 6.3 ± 1.2, respectively. Overall, there was no net significant annualized change in PAV (least-squares mean ± standard error: 0.14 ± 0.15, P = 0.38). Table 3 Similarly, the average on-treatment values correlated significantly with PAV progression [LDL-C: 0.119 (0.085, 0.15), P < 0.001; non-HDL-C: 0.14 (0.11, 0.18), P < 0.001; TC/HDL-C: 0.15 (0.11, 0.19), P < 0.001; ApoB 0.09 (0.045, 0.14), P < 0.001]. In this case, average on-treatment HDL-C was significantly associated with PAV regression [-0.075 (-0.12, -0.032), P < 0.001]. Notably, there was not a significant association between LDL-C variability and annualized change in PAV in the population with achieved LDL-C levels <70 mg/dL [0.066 (-0.01, 0.14), P = 0.089]. In the same population however, there was a significant and stronger association between annualized change in PAV and average on-treatment LDL-C [0.14 (0.032, 0.26), P = 0.012]. 11.4%, all log-rank P < 0.01). There was not a significant difference on incidence of MACE between any pair of SD quartiles of HDL-C (overall P = 0.30). For these analyses, similar results are seen when measuring lipoprotein variability using average successive variability, as presented in Supplementary material online, Tables SI and SII.
Results
Discussion
In this post hoc patient-level analysis of nine clinical trials utilizing serial coronary IVUS, we demonstrate that greater visit-to-visit variability in atherogenic lipoprotein levels is independently associated with coronary atheroma progression and adverse cardiovascular outcomes. Our results confirm prior work demonstrating cholesterol variability as a predictor of cardiovascular events [1] [2] [3] and further extend these findings across a range of atherogenic lipoprotein measurements including LDL-C, non-HDL-C, TC/HDL-C, and ApoB. The present analysis is the first to demonstrate that atherogenic lipoprotein variability is directly associated with a proatherosclerotic process, thereby providing a plausible mechanism linking this variability with the increased risk of cardiovascular events. The association however, between achieved lipoproteins and changes in coronary atheroma volume was comparatively stronger, highlighting the importance of aggressively lowering atherogenic lipoproteins in atrisk individuals. Recent analysis of the treating to new targets (TNT) trial demonstrated that LDL-C visit-to-visit variability predicts cardiovascular events independent of achieved LDL-C levels. 1 These findings raised the possibility that LDL-C variability may represent a phenomenon contributing to residual risk among those with coronary artery disease already receiving optimal medical therapy. Subsequent analysis from the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) trial demonstrated that higher visit-to-visit LDL-C variability was associated with lower neurocognitive performance, lower cerebral blood flow, and greater white matter hyperintensity on brain magnetic resonance imaging. 2 Additionally, cholesterol variability was
shown to associate with all-cause mortality, MI, and stroke in a large cohort broadly representative of the general Korean population. 3 The association with cholesterol variability and cardiovascular outcomes now seems established; however, in order to target future interventions it is important to delineate pathophysiologic characteristics linking laboratory findings and clinical outcomes. Although the possibility for unmeasured confounders cannot be excluded in the present analysis, the clear association between atherogenic lipoprotein variability and plaque progression suggests a cholesterol-mediated proatherosclerotic effect as compared with a more general homeostatic imbalance affecting cardiovascular risk through other pathophysiologic mechanisms. The biological mechanisms underlying lipoprotein variability and the association with atheroma progression warrants further investigation. Multivariable modelling in the current analysis considered a number of potentially important factors including glucose control, BMI, concomitant statin use, and baseline lipid measurements. It is widely recognized that statins promote atheroma regression likely through reductions of the lipid, inflammatory, and necrotic plaque components. 6 One hypothesis is that lipoprotein variability hinders lipid efflux from atheroma resulting in ongoing plaque volume progression (attenuating the effects of risk-modifying therapies); a process that significantly associates with incident cardiovascular events. [16] [17] [18] [19] Therapeutic means of lowering atherosclerotic and cardiovascular risk is fundamentally based on LDL-C reduction. However, among those who achieve low LDL-C levels, additional lipoproteins including TG, non-HDL-C, and Apo B contribute to residual risk. Furthermore, TC/HDL-C more accurately identifies atheroma progression and may better reflect atherogenic lipid particles, especially when LDL-C, Apo B, and non-HDL-C levels are discordant. 20 The current analysis supports that variability of all lipoproteins is associated with plaque progression, and it is important to note the absence of association with HDL-C variability which is consistent with lack of benefit seen drug trials targeting HDL-C. The results of this analysis support the role of variability not only with LDL-C but also other atherogenic lipoproteins, and further research is required to better understand the mechanism underscoring these findings.
The results of this analysis may have implications when considering the management of patients at risk for atherosclerotic heart disease. Among patients receiving statin therapy, current guidelines recommend periodic monitoring of lipid levels to assess adherence and therapeutic response. [21] [22] [23] The present analysis suggests that serial lipid level monitoring is important to identify variability, in addition to statin hyporesponders, in order to intensify broader preventive therapy in higher-risk individuals. 24 Also, intermittent statin dosing is an increasingly employed treatment strategy in statin intolerant patients based on effective LDL-C lowering in observational studies, 25 yet these patients have substantially higher rates of cardiovascular events than those without statin intolerance. 26 On-treatment atherogenic lipoprotein levels were found to harbour a more robust association with changes in atheroma volume, highlighting the well-established importance of aggressively lowering lipoprotein levels. These findings also lend further support to the 'lower is better' notion of LDL-C lowering, recently illustrated by the complementary findings of the GLAGOV and FOURIER randomized trials involving aggressive LDL-C with evolocumab. 27, 28 However, the present analysis also suggests that stability, in addition to reduction, may be an important consideration among statin intolerant patients who often require multiple medication regimen changes. Further studies are needed to assess the relationship between medication dosing, lipid reduction, lipid stability, and cardiovascular events. Several caveats of the current analysis warrant further consideration. This analysis is limited to patients enrolled in clinical trials with established coronary artery disease with an indication for coronary angiography and may not be applicable to those without documented atherosclerotic heart disease. Despite a rigorous statistical approach and relatively uniform inclusion/exclusion criteria in each trial, unmeasured confounding biasing the results cannot be excluded. Lipid measurements used in the variability assessment were obtained throughout the trial and therefore may introduce bias among those with non-fatal MACE prior to the end of follow-up. This limits the interpretation of the relationship between lipoprotein variability and MACE, and it is important emphasize that these findings represent an association and are thus considered hypothesis generating. On the other hand, the present data are unique in analysing a variety of lipoprotein variables across multiple clinical trials using appropriate statistical means to account for both confounders and the range of trialled therapies included in this analysis. Detailed pill counts were not a routine part of the serial IVUS trials included in this analysis; however, compliance rates were shown to be systematically >90% across these trials, thereby minimizing the issue of medication noncompliance significantly influencing the results.
In conclusion, in patients with coronary artery disease receiving established medical therapies, greater visit-to-visit variability in atherogenic lipoprotein levels significantly associates with coronary atheroma progression and adverse clinical outcomes. These observations, coupled with stronger associations between achieved lipoprotein levels and plaque progression-regression, highlight the dual importance of not only aggressively lowering atherogenic lipoproteins levels but also achieving stable reductions. Further research is required to unravel mechanisms promoting lipoprotein variability, including its therapeutic implications.
